X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2922) 2922
life sciences & biomedicine (2788) 2788
humans (2785) 2785
niacinamide - analogs & derivatives (2174) 2174
male (1806) 1806
female (1462) 1462
oncology (1454) 1454
animals (1172) 1172
middle aged (1145) 1145
sorafenib (1145) 1145
phenylurea compounds - administration & dosage (1070) 1070
phenylurea compounds (1060) 1060
aged (993) 993
phenylurea compounds - therapeutic use (851) 851
antineoplastic agents - therapeutic use (827) 827
treatment outcome (799) 799
phenylurea compounds - pharmacology (772) 772
adult (741) 741
liver neoplasms - drug therapy (706) 706
carcinoma, hepatocellular - drug therapy (678) 678
niacinamide - administration & dosage (668) 668
cancer (589) 589
mice (571) 571
pyridines - administration & dosage (565) 565
phenylurea compounds - adverse effects (562) 562
pharmacology & pharmacy (556) 556
antineoplastic agents - administration & dosage (555) 555
pyridines - therapeutic use (549) 549
niacinamide - therapeutic use (529) 529
hepatocellular carcinoma (499) 499
care and treatment (489) 489
antineoplastic agents - adverse effects (478) 478
antineoplastic agents (467) 467
antineoplastic combined chemotherapy protocols - therapeutic use (461) 461
carcinoma, renal cell - drug therapy (453) 453
kidney neoplasms - drug therapy (450) 450
antimitotic agents (448) 448
cell line, tumor (441) 441
liver neoplasms - pathology (440) 440
protein kinase inhibitors - therapeutic use (438) 438
benzenesulfonates - administration & dosage (432) 432
carcinoma, hepatocellular - pathology (418) 418
benzenesulfonates - therapeutic use (403) 403
aged, 80 and over (401) 401
liver cancer (364) 364
dose-response relationship, drug (359) 359
pyridines - adverse effects (359) 359
rats (353) 353
disease-free survival (347) 347
analysis (338) 338
niacinamide - adverse effects (337) 337
antineoplastic agents - pharmacology (336) 336
drug therapy (324) 324
medicine & public health (321) 321
metastasis (320) 320
research (317) 317
hepatoma (310) 310
protein kinase inhibitors - administration & dosage (310) 310
tumors (302) 302
chemotherapy (290) 290
retrospective studies (285) 285
protein kinase inhibitors - adverse effects (278) 278
cell proliferation - drug effects (275) 275
niacinamide - pharmacology (266) 266
benzenesulfonates - adverse effects (259) 259
kidney neoplasms - pathology (259) 259
prognosis (258) 258
gastroenterology & hepatology (253) 253
vascular endothelial growth factor (251) 251
pyridines - pharmacology (246) 246
neoplasm staging (243) 243
apoptosis - drug effects (234) 234
cancer therapies (227) 227
digestive system diseases (224) 224
protein kinase inhibitors - pharmacology (223) 223
kinases (217) 217
xenograft model antitumor assays (217) 217
apoptosis (216) 216
neoplasms (213) 213
phenylurea compounds - pharmacokinetics (210) 210
clinical trials (209) 209
neoplasms - drug therapy (208) 208
disease progression (207) 207
administration, oral (202) 202
antineoplastic combined chemotherapy protocols - adverse effects (201) 201
renal cell carcinoma (196) 196
indoles - therapeutic use (195) 195
patients (195) 195
time factors (194) 194
angiogenesis (192) 192
kaplan-meier estimate (192) 192
neoplasm metastasis (190) 190
pyrroles - therapeutic use (186) 186
signal transduction - drug effects (182) 182
indoles - administration & dosage (181) 181
abridged index medicus (180) 180
bevacizumab (179) 179
drug administration schedule (179) 179
mice, nude (179) 179
health aspects (177) 177
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3311) 3311
Japanese (55) 55
German (32) 32
French (17) 17
Chinese (16) 16
Portuguese (5) 5
Russian (5) 5
Spanish (4) 4
Hungarian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Dutch (1) 1
Italian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European journal of cancer (1990), ISSN 0959-8049, 11/2013, Volume 49, Issue 16, pp. 3412 - 3419
Abstract Purpose We assessed the safety of the multikinase inhibitor regorafenib in patients with hepatocellular carcinoma (HCC) that had progressed following... 
Hematology, Oncology and Palliative Medicine | Second line | Regorafenib | Hepatocellular carcinoma | Tolerability | Safety | Receptor kinase inhibition | Safety Second line | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - mortality | Pyridines - adverse effects | Carcinoma, Hepatocellular - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Liver Neoplasms - pathology | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Liver Neoplasms - enzymology | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Treatment Outcome | Carcinoma, Hepatocellular - enzymology | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Neoplasm Staging | Care and treatment | Safety and security measures | Hepatoma | Index Medicus
Journal Article
Nature (London), ISSN 0028-0836, 09/2016, Volume 538, Issue 7625, pp. 344 - 349
Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compounds... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Azabicyclo Compounds - pharmacology | Plasmodium falciparum - enzymology | Malaria, Falciparum - prevention & control | Male | Plasmodium falciparum - cytology | Azetidines - pharmacology | Plasmodium falciparum - drug effects | Cytosol - enzymology | Malaria, Falciparum - transmission | Liver - drug effects | Azabicyclo Compounds - chemical synthesis | Azabicyclo Compounds - therapeutic use | Female | Safety | Antimalarials - chemical synthesis | Disease Models, Animal | Life Cycle Stages - drug effects | Malaria, Falciparum - drug therapy | Azabicyclo Compounds - administration & dosage | Azetidines - adverse effects | Phenylurea Compounds - therapeutic use | Antimalarials - therapeutic use | Macaca mulatta - parasitology | Phenylalanine-tRNA Ligase - antagonists & inhibitors | Drug Discovery | Antimalarials - pharmacology | Animals | Azetidines - administration & dosage | Phenylurea Compounds - chemical synthesis | Antimalarials - administration & dosage | Azetidines - therapeutic use | Phenylurea Compounds - administration & dosage | Mice | Phenylurea Compounds - pharmacology | Liver - parasitology | Plasmodium falciparum - growth & development | Prevention | Antimalarials | Disease transmission | Health aspects | Transfer RNA | Proteins | Cytochrome | Malaria | Liver | Parasites | Kinases | Drug resistance | Drug dosages | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 05/2016, Volume 387, Issue 10032, pp. 2008 - 2016
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2014, Volume 384, Issue 9940, pp. 319 - 328
Journal Article
The lancet oncology, ISSN 1470-2045, 10/2015, Volume 16, Issue 13, pp. 1344 - 1354
Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy... 
Hematology, Oncology and Palliative Medicine | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 06/2013, Volume 24, Issue 6, pp. 1560 - 1567
Journal Article
Journal of gastroenterology, ISSN 1435-5922, 10/2016, Volume 52, Issue 4, pp. 512 - 519
Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor... 
E7080 | Medicine & Public Health | Colorectal Surgery | Tyrosine kinase inhibitor | Hepatology | Gastroenterology | Abdominal Surgery | Hepatocellular carcinoma | Vascular endothelial growth factor inhibitor | Lenvatinib | Surgical Oncology | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Body Weight | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Carcinoma, Hepatocellular - diagnostic imaging | Young Adult | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Drug Administration Schedule | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Liver Neoplasms - diagnostic imaging | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Quinolines - therapeutic use | Neoplasm Staging | Quinolines - adverse effects | Tyrosine | Complications and side effects | Medical research | Care and treatment | Medicine, Experimental | Hepatoma | Growth factors | Endothelium | Index Medicus | Original —Liver, Pancreas, and Biliary Tract
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 05/2015, Volume 51, Issue 8, pp. 942 - 949
Journal Article